Navigation Links
Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products

DOYLESTOWN, Pa., June 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today advised consumers to stop using three intra-nasal products (gels and swabs) marketed over-the-counter as cold remedies under the Zicam(R) brand because the use of these intra-nasal products are associated with the loss of sense of smell (a condition called anosmia).

While these products are manufactured with a zinc ingredient, The Quigley Corporation (Nasdaq: QGLY),, maker of the popular line of Cold-EEZE(R) zinc gluconate lozenges, assures consumers that their oral zinc lozenge products are not involved in this new FDA advisory, and that the Cold-EEZE(R) brand continues to be supported as safe and effective in clinical research. Only intra-nasal products have shown any association with anosmia.

"The introduction of zinc ions orally has not been connected with the loss of smell," says Darrell T. Hulisz, R.Ph., PharmD, clinical pharmacist/researcher and associate clinical professor at Ohio Northern University College of Pharmacy. "The safe and efficacious use of oral zinc gluconate lozenges is well established."

"The FDA has made a determination that the Zicam intra-nasal products have a growing body of evidence suggesting that they may pose a safety risk to consumers who use them," says Albert Piechotta, executive director of communications at The Quigley Corporation. "Cold-EEZE zinc lozenges have been shown to safely reduce the duration and severity of cold symptoms by nearly half in two clinical studies and have no history of causing adverse events related to anosmia in clinical studies or safety studies."

Since their introduction 14 years ago, Cold-EEZE lozenges have had an outstanding record of safety. Customers can be assured that Cold-EEZE lozenges will continue to be available and is not affected by the FDA's decision to request Zicam remove its nasal products from store shelves."

For more information about Cold-EEZE(R), visit

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. ( conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    Media Contact:
    Alyson O'Mahoney
    Robin Leedy & Associates
    (914) 241-0086, ext. 13
    Albert Piechotta, Executive Director of Communications
    The Quigley Corporation
    (215) 345-0919, ext. 122

    Investor Relations Contact:
    Carl Hymans
    G.S. Schwartz & Co.
    212-725-4500-ext 304

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Product Release: CraniYums(R) App-Suppress(TM) Candy-Like Lozenges, with Pinnothin(R) - a Proven Appetite Suppressant.
2. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
3. A childs IQ could be affected by maternal epilepsy
4. Sexual function affected by stem cell transplant according to long-term study
5. Patients perceived cancer care unaffected by lower Medicare reimbursements
6. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
7. Aetna Reminds Members Affected by California Wildfires Where to Call for Help
8. AutismCares Offers Support to Families Affected by California Fires
9. UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires
10. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
11. American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons Offer Patient Advisory for those Affected by Fig LipoDissolve Closures
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: